Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Travere Therapeutics
Biotech
Amicus pays Dimerix $30M for late-phase rare kidney disease drug
Amicus has bagged U.S. rights to the phase 3 prospect DMX-200, establishing it as a challenger to Travere Therapeutics in a rare kidney disease.
Nick Paul Taylor
May 1, 2025 10:59am
Travere fails to beat off-label blood pressure drug in phase 3
May 2, 2023 7:00am
FDA’s liver safety request set to delay decision on Travere drug
Oct 14, 2022 10:05am
Vifor doles out $55M upfront to license Travere's asset
Sep 16, 2021 11:41am
FDA sets back Travere's plans for kidney disease drug approval
May 26, 2021 8:10am
Retrophin sheds Shkreli connection with new name: Travere
Nov 17, 2020 10:30am
